Gonzalez-Ramirez D, Zuniga-Charles M, Narro-Juarez A, Molina-Recio Y, Hurlbut K M, Dart R C, Aposhian H V
Department of Pharmacology,, Centro de Investigacion Biomedica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, Mexico.
J Pharmacol Exp Ther. 1998 Oct;287(1):8-12.
DMPS (2,3-dimercaptopropane-1-sulfonate, Na salt), when used as a challenge test for mercury in workers involved in the production of a calomel skin-bleaching lotion and in direct contact with mercurous chloride, elevated urine levels of mercury. A DMPS treatment regimen was devised and initiated. Three days after the challenge test, DMPS was administered p.o. (400 mg per day) for 8 days, followed by a no-treatment period of five days. A new cycle of DMPS treatment for 7 days was initiated and followed by 5 days without treatment. A third period of treatment was begun for 6 days, followed by a 5-day no-treatment period. The urinary mercury greatly increased during those periods when DMPS was administered (1754, 314, and 173 microgram/24 h for the periods 1, 2 and 3, compared with 106, 48 and 53 microgram/24 h on the corresponding no-treatment periods). One of the workers presented signs of drug intolerance and was discharged after receiving the first cycle of treatment. DMPS treatment was effective in lowering the body burden of mercury and in decreasing the urinary mercury concentration to normal levels.
二巯基丙磺酸钠（DMPS，2,3 - 二巯基丙烷 - 1 - 磺酸钠盐）在用于对参与甘汞皮肤美白乳液生产且直接接触氯化亚汞的工人进行汞激发试验时，会使尿汞水平升高。于是设计并启动了一个DMPS治疗方案。激发试验三天后，口服DMPS（每天400毫克），持续8天，随后有5天不进行治疗。接着开始新的DMPS治疗周期，为期7天，之后又是5天不治疗。开始第三个治疗阶段，为期6天，随后是5天不治疗期。在服用DMPS的期间，尿汞大幅增加（第1、2和3阶段分别为1754、314和173微克/24小时，而相应的未治疗期间分别为106、48和53微克/24小时）。其中一名工人出现药物不耐受迹象，在接受第一个治疗周期后出院。DMPS治疗在降低体内汞负荷以及将尿汞浓度降至正常水平方面是有效的。
